These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28508354)

  • 1. Patient and Public Preferences for Treatment Attributes in Parkinson's Disease.
    Weernink MGM; van Til JA; Groothuis-Oudshoorn CGM; IJzerman MJ
    Patient; 2017 Dec; 10(6):763-772. PubMed ID: 28508354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
    Marshall T; Pugh A; Fairchild A; Hass S
    Value Health; 2017 Dec; 20(10):1383-1393. PubMed ID: 29241898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involving Patients in Weighting Benefits and Harms of Treatment in Parkinson's Disease.
    Weernink MG; van Til JA; van Vugt JP; Movig KL; Groothuis-Oudshoorn CG; IJzerman MJ
    PLoS One; 2016; 11(8):e0160771. PubMed ID: 27575744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australian Public Preferences for the Funding of New Health Technologies: A Comparison of Discrete Choice and Profile Case Best-Worst Scaling Methods.
    Whitty JA; Ratcliffe J; Chen G; Scuffham PA
    Med Decis Making; 2014 Jul; 34(5):638-54. PubMed ID: 24713695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?
    Veldwijk J; Essers BA; Lambooij MS; Dirksen CD; Smit HA; de Wit GA
    Value Health; 2016; 19(2):202-9. PubMed ID: 27021754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs.
    Atkinson-Clark E; Charokopou M; Van Osselaer N; Hiligsmann M
    Epilepsy Behav; 2018 Feb; 79():58-67. PubMed ID: 29248866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective.
    Johnston KM; Audhya IF; Dunne J; Feeny D; Neumann P; Malone DC; Szabo SM; Gooch KL
    Appl Health Econ Health Policy; 2024 May; 22(3):343-352. PubMed ID: 38253973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.
    Weernink MG; Groothuis-Oudshoorn CG; IJzerman MJ; van Til JA
    Value Health; 2016; 19(2):226-32. PubMed ID: 27021757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients accept therapy using embryonic stem cells for Parkinson's disease: a discrete choice experiment.
    Bywall KS; Drevin J; Groothuis-Oudshoorn C; Veldwijk J; Nyholm D; Widner H; van Vliet T; Jiltsova E; Hansson M; Johansson JV
    BMC Med Ethics; 2023 Oct; 24(1):83. PubMed ID: 37828462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment.
    Lloyd AJ; Gallop K; Ali S; Hughes D; MacCulloch A
    Curr Med Res Opin; 2017 Jan; 33(1):23-29. PubMed ID: 27590169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Analytic Hierarchy Process and Discrete-Choice Experiment to Elicit Patient Preferences for Treatment Characteristics in Age-Related Macular Degeneration.
    Danner M; Vennedey V; Hiligsmann M; Fauser S; Gross C; Stock S
    Value Health; 2017 Sep; 20(8):1166-1173. PubMed ID: 28964450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient preferences for treatment of low back pain-a discrete choice experiment.
    Kløjgaard ME; Manniche C; Pedersen LB; Bech M; Søgaard R
    Value Health; 2014 Jun; 17(4):390-6. PubMed ID: 24968999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preference for a long-acting recombinant FSH product in ovarian hyperstimulation in IVF: a discrete choice experiment.
    van den Wijngaard L; Rodijk IC; van der Veen F; Gooskens-van Erven MH; Koks CA; Verhoeve HR; Mol BW; van Wely M; Mochtar MH
    Hum Reprod; 2015 Feb; 30(2):331-7. PubMed ID: 25432926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the General Public Be a Proxy for an "At-Risk" Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis.
    DiSantostefano RL; Simons G; Englbrecht M; Humphreys JH; Bruce IN; Bywall KS; Radawski C; Raza K; Falahee M; Veldwijk J
    Med Decis Making; 2024 Feb; 44(2):189-202. PubMed ID: 38240281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.
    Mühlbacher AC; Bridges JF; Bethge S; Dintsios CM; Schwalm A; Gerber-Grote A; Nübling M
    Eur J Health Econ; 2017 Mar; 18(2):155-165. PubMed ID: 26846922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment possibilities in advanced Parkinson's disease].
    Takáts A; Nagy H; Radics P; Tóth A; Tamás G
    Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep brain stimulation improves survival in severe Parkinson's disease.
    Ngoga D; Mitchell R; Kausar J; Hodson J; Harries A; Pall H
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):17-22. PubMed ID: 23843542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous perioperative apomorphine in deep brain stimulation surgery for Parkinson's disease.
    Slotty PJ; Wille C; Kinfe TM; Vesper J
    Br J Neurosurg; 2014 Jun; 28(3):378-82. PubMed ID: 24073755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes.
    Guimarães C; Marra CA; Colley L; Gill S; Simpson S; Meneilly G; Queiroz RH; Lynd LD
    Diabetes Technol Ther; 2009 Sep; 11(9):567-73. PubMed ID: 19764835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.